Skip to main content
KARD $12.52 +1.62%
KARD logo
KARD · Kardigan, Inc.
Track KARD — free
$12.52 +0.20 (+1.62%)
Market Cap
$1.17B
Shares
93.60M
Volume · Nov 19 977.81K Avg daily vol (3M) 615.72K
All webcasts

Conference · 2026-11-18

Kardigan, Inc. (KARD) November 18, 2026 Conference Transcript

Concluded Nov 18, 2026 Audio replay
Nov 18, 2026 26:32 43 turns
Period
2026-11-18
Runtime
26:32
Sources
2 artifacts

Transcript & audio

26:32 Audio
Dennis Ding Analyst — Jefferies

All right. Good afternoon. Welcome to the Jefferies London Healthcare Conference. My name is Dennis Ding, biotech analyst here at Jefferies. I have the wonderful pleasure of hosting Cardigan here with us. We have CEO Tassos Janakakos and also Cheryl Abbas, director of research. So welcome.

Thank you, Dennis.

Dennis Ding Analyst — Jefferies

So before we kind of dig into the programs, and there are a lot of things going on, just talk about 2026 and what that meant for you as a newly public company.

Yeah, 2026 was a pretty foundational year for us. As you mentioned, we went public. We launched our three programs, like, really kind of deeply, regulatory guidance intact. We finished enrolling our Phase II portions of two of the three programs, DENICAMTIF, the TASIGWAT, and we've got our TLA program now enrolling with most of the sites active. We learned a lot in the year. We learned a lot, and you'll hear about, I think, in some of the discussion we're going to have today. We adapt, like, a very clear approach where we learn early from our clinical trials and adjust as we go. We've done that in adaptive programs with DentaCaptive. We've seen that in Atasavad with some data and some analysis that we shared just a week ago at the American Heart Association that Cheryl can get into a little bit, and we're learning about these patients that have really difficult to treat hypertension. So all of that is part of the plan, and it improves all of our downstream chances of success, and that is something unique in cardiology, not unique in other therapeutic areas, for For sure. And I think this approach, more than ever, is very necessary in the world's leading kind of therapeutic burden category, cardiology. We've seen the Horizon results. We've seen Zeus results. A reaction from people may be, oh, my goodness, you know, cardiovascular development is very challenging, and we should maybe divert. That's the wrong approach. I think the way to think about it is we need a different way to go. And I think Cardigan and how we approach our clinical trials and our development paradigm is exactly the answer, I would say, to these long, costly outcome studies. So as we think about exiting 2026, Dennis, we're into now a really nice spot with our programs going into 27, where a very steady flow of highly de-risking data coming from each and every one of our programs, starting in the second quarter with Dan and Camtiv.

Dennis Ding Analyst — Jefferies

Yeah, and I think that's spot on because, you know, I feel like there's this big concern around event rates and event rates slowing down because of better standard of care, and I can understand how that could impact CBOTs, but you guys aren't even running CBOTs.

Yeah, that's right. I mean, I think when you start looking at addressing with targeted medicines the drivers of disease, it opens up the field for imaging, circulating biomarkers, other markers that are directly correlative to improvements in... function or in symptoms, and ultimately in outcomes. But in each of our disease areas, we're first in disease. So DCM, no-approved therapies. Aortic stenosis, no-approved therapies. And for these severe hypertension patients, no-approved therapies. And with targeted medicines, it's exactly right. You have all of these tools. Again, these tools are common and well-utilized. Basket trials, adaptive trials, and other TAs. We just need to be doing it in cardiology, and we've had success doing that, right? We've had success in the previous company, and so far, we've shown success here at Cardigan.

Dennis Ding Analyst — Jefferies

Perfect. So... You know, you have three products in Phase 2B. All three will have data next year. Maybe we can focus on the first one, which is the anacamp of Q2 data. Maybe just talk about, you know, the opportunity here. How big is it in the U.S., but also perhaps globally? And just remind us of the prior data you guys have shown in Phase 2A. Do you want to take that?

Cheryl Abbas Other

Yeah, sure. So when we think about DCM, it's actually the leading cause of heart transplantation in the U.S. A vast majority of patients with heart failure with reduced ejection fraction have DCM. When we layer into genetic DCM, it's about 1 in 250, so in general, about 50,000 patients with diagnosed genetic DCM in the U.S., specifically comprising mostly myosin, heavy chain 7, and Titan genetic variants. And then when we dig a little bit deeper, when you look at other genetic causes, that's upwards of 200,000 patients, also specific to that of the U.S. The census is very similar to that in the ex-U.S. footprint. In particular, in the E.U., genetic testing is well done, and so these patients typically exist in, like, biobanks, such as in the U.K., here in the U.K., and outwards in the E.U., and this is a global trial. So we're actively enrolling patients in both the EU and the U.S. for that purpose.

Dennis Ding Analyst — Jefferies

Perfect. So what should investors be looking for, you know, at that update in Q2, right? You guys have cohort one, cohort two, and you're measuring a bunch of different parameters, but like what is your messaging and how do you frame that?

Cheryl Abbas Other

Yeah, so the six-month data in Kinship DCM really allows us to replicate the echocardiographic parameters that Danik-Kamtiv showed to improve in the Phase II way. So we're looking at the totality of evidence across how Danik-Kamtiv improves the left atrium, the left ventricle, specific to parameters such as left ventricular ejection fraction, global longitudinal strain. So that's a measure of how well the heart squeezes to produce stroke volume. We're also even going to look at the right ventricle. We recently presented data at the European Society of Cardiology that demonstrated preclinical and clinical evidence with improvements in RV function, which is important in this population. All of those parameters, in some way, we know correlate to the change in peak VO2. At week 26, at six months, and that is the Q2 top-line data, we'll have those echocardiographic parameters as well as the change in peak VO2 as a directional trend. It's not powered for that, but we'll be able to show the correlations between echocardiographic improvements and the change in peak VO2, which gives us a direct read to the Phase 3. That's the opportunity where peak VO2 is the primary registrational endpoint in the Phase 3 trial, and we'll be able to really adjust the statistical analysis plan based upon those correlations.

Dennis Ding Analyst — Jefferies

So in the phase 2A study that you guys ran, so most patients were only on a couple weeks of therapy. So like what gives you confidence that some of the signals that you saw there in two weeks is sustainable and durable and perhaps may even grow over time out to six months?

Cheryl Abbas Other

Yeah, so the phase 2A data, the first cohort was analyzed at two weeks. So we have rapid evidence of the effect of Danicam tip across the echocardiographic parameters that I mentioned. So left atrial functional index over an 8.0% change, left ventricular ejection fraction, as well as left ventricular global longitudinal strain. The early improvements at two weeks were sustained through the open-label extension in Part B, where patients were followed up to 12 weeks, but we have some patients that were even followed up to one year. Typically, when you look at patients of this type of phenotype, when you see echocardiographic parameters that change as a rapid onset, you know that there's reverse remodeling that will be sustained thereafter. That's what we're going to show at the week 26 or the six-month endpoint in Q2 of next year. But the early onset of effect and the sustained effect in the open-label extension gives us great confidence that we'll see the same thing in kinship DCM, But also that these will translate to a meaningful improvement in peak VO2.

Dennis Ding Analyst — Jefferies

Right. And I think what you said there was really critical around reverse remodeling. It's not just one echo parameter that's getting better at two weeks. The totality of things, right? They're looking better. And once you take some of that stress and load off of the heart, that gives the heart. the opportunity to remodel. That's right. So will we see evidence of that at the six-month update in Q2?

Cheryl Abbas Other

That's what we hope to show with those echocardiographic parameters. If we replicate exactly what we saw in the phase 2a, that would be the data that we would share. Absolutely. And I would say that those echocardiographic parameters in this population are known to translate to improvements in symptomatology, as Tasso said, but even outcomes. I mean, drugs that reverse remodel We'll improve heart failure outcomes. So it gives us significant confidence if we're able to replicate the phase 2A, but more importantly, even just get the appropriate correlations to the change in peak VO2 to de-risk the phase 3.

So if you think about the comparison between the 2B and the 2A, same patients. We're treating for longer. We have a larger study, so we're hoping and expecting to see similar results on the heart function, EF, GLS, LAFI. The one piece of data that we don't have yet because it hasn't been studied is their correlation to peak VO2. We are going to get that. That then allows you to confirm your powering assumptions for phase three. If we see correlations that are similar to those published, then we're properly sized at 250 patient or subject phase three. If we need to adjust, we have the opportunity to adjust. And that study is a seamless phase two B3. So we are enrolling phase three now, so it's going to be easy to adjust on the fly and without losing any time or momentum.

Dennis Ding Analyst — Jefferies

Is there any particular echo parameter that has a good correlation with peak VO2?

Cheryl Abbas Other

Yeah, GLS is known to have the strongest correlation in general heart failure with reduced ejection fraction in also patients with DCM in general. There hasn't been a dedicated study in genetic DCM, which is what we will show at the six-month data, as Tasso was saying. But generally speaking, we still look at the totality of evidence, right? And you mentioned this, Dennis. When you think about how you improve cardiopulmonary function, you want to improve filling and you want to improve stroke volume. And that's why we measure and we saw improvements in left atrial functional index, which improves filling into the left ventricle, and we improved stroke volume, GLS. And that would translate to a clinically meaningful change in peak VO2.

Dennis Ding Analyst — Jefferies

Got it. And on the safety side, what are you guys looking out for, and how do we get comfortable around some of these? The asymptomatic troponin elevations that you guys have had before?

Cheryl Abbas Other

So the asymptomatic troponin elevations were seen in the other non-sarcomeric genetic variant cohort in the phase 2a. There were three cases. They were transient, none of which were ischemic, and so the elevations were not at a significant magnitude that would cause concern relative to ischemia. They were also at a magnitude that is generally relatable to just exercise, so none that were really clinically significant, and so it doesn't give us great pause, in particular for our own study. We've been through an IDMC. We continue to proceed at their disclosures.

Dennis Ding Analyst — Jefferies

Sure. Um, and I... I believe also the way that you guys are dosing 50 mx BID, the exposure of that is below the exposure that you guys have, where I think there was only one symptomatic.

Cheryl Abbas Other

There was only one case of that.

Dennis Ding Analyst — Jefferies

But the exposure of that was just way above where you guys are dosing.

Cheryl Abbas Other

Correct, and it was in the other cohort, for which if you really actively engage myosin, you could potentially put patients at risk. And this is where the mechanism of action is really renders to the actual sarcomeric variants, but we're going to learn from the non-sarcomeric variants in cohort two. But so far, again, from a safety perspective, we're doing just fine. And those elevations were very transient, not at a significant magnitude.

Dennis Ding Analyst — Jefferies

Okay. When people try to compare Danicamptiv with Omicamptiv. What do you say to that, and how do we see that it's different through some of the ECHO data?

So they're very different mechanisms. So while they are both in the category of myosin activators, they bind slightly differently. And when we were at Myocardia, who discovered this drug, I was there at the time as CEO, we had the benefit of understanding the biochemical kind of assay cascade and then the clinical readout of omacampin. So we were able to dial out. Essentially, what we saw there was an increase in systolic ejection time based on the mechanism, which is how omacaptive increases stroke volume, and that can reduce diastolic filling time. Now, there is a PK-based approach to dose that, which manages this phenomenon, but we don't have that. We designed Danicamptiv specifically to increase the force of contraction without impairing diastole. Without impairing diastole, and so as a result, We don't see any of that. We have no need for a dose titration, certainly not a PK dose titration. It's a fixed dose. And the other part of it is we are treating a very different patient population. We are focused on genetic familial cardiomyopathy and on the dilated type where the issue is exactly the one that Danikamp was designed to address. So when you think about that, we're effectively restoring normal contractility, and we are seeing that by these essentially non-effects on troponin, et cetera, with pretty staggering improvements in LV function in just two weeks. That's not something you would see with other compounds.

Cheryl Abbas Other

Maybe to double-click, Dennis, you asked about the difference in echo. So this is a good example where I mentioned that peak VO2 is related to stroke volume and filling pressures, the diastole. So peak VO2 is really not a great endpoint for a drug like omacamtiv because of the impairment on systolic ejection time, which would essentially impair diastolic filling. So it's counterintuitive there. When you look at the echocardiographic parameters and the correlations to peak VO2, treatment with omacamtiv in a general HFREF patient population, that's an important distinction from our approach, GLS improved by 0.9% in the Meteorics trial. And again, it didn't really result in a change in peak VO2 because of the impairments to diastolic filling. So with Danikamtev, we saw a 1.6% change in GLS in the Phase 2a study.

Dennis Ding Analyst — Jefferies

Maybe we can move on to your second asset, Adis Sijwad.

Cheryl Abbas Other

You got it. ATA.

Dennis Ding Analyst — Jefferies

I tried. You guys had some updates at AHA just a couple weeks ago. Remind us what they were and just how to overall think about phase 2P next year.

Cheryl Abbas Other

Yeah, so AHA was a good moment for us as I feel like we really are pioneering the field in aortic stenosis. At AHA, the top-line message was we are now learning, and the field is now learning, that aortic stenosis is a disease of the valve and the ventricle. So we presented two data sources. One was our baseline demographics of the Catalyst AV trial. The second was a real-world evidence analysis in a database of about 45,000 patients with mild and moderate aortic stenosis. On the baseline demographics, we learned that calcium is widely distributed across a narrow range of aortic valve area, across a range of AVA of 1 to 1.5. That was unexpected. You would typically think that patients who have a more narrow valve, a lower AVA at baseline, would have a higher calcium burden. We didn't see that across all patients. It's widely distributed and not really correlative. So it does show that the variability at baseline really means that we need more time for the placebo arm to progress and to be able to really ascertain how the drug is modifying calcium relative to a measure like AVA, which is most predictive of progression, and, quite frankly, also a potential future registrational endpoint. So being able to assess calcium relative to how the drug is modifying AVA and its direct effect on the ventricle allows us to do so at a year in a time frame that would be clinically interpretable and would provide the full clinical context of the disease progression. That's on the baseline. On the real-world analysis, what we sought to understand is who are these rapid progressors whose AVA declines much more quickly. What we found is that patients who have evidence of cardiac damage, otherwise known as myocardial dysfunction, are more likely to progress quickly, so they have a faster rate of decline in aortic valve area, but they also have worsening outcomes compared to patients who do not have cardiac damage at baseline. So worsening outcomes includes time to TAVR, worsening heart failure, even new onset heart failure. That's really important for a drug like Atosaguat, where we know this drug modifies the valve and the ventricle. So that data allows us to apply potential enrichment criteria in our Phase III study to be able to enroll patients who may progress more rapidly, but also where it's really conducive to the mechanism of action. And so we'll share more data in the first half of next year on the Phase III trial. The last thing I'll say is there was a thought that these patients who are symptomatic really don't exist, or these patients who have evidence of cardiac dysfunction are more in the severe range. What we found is that 80% of patients with mild and moderate aortic stenosis have evidence of cardiac damage. We saw that in our real-world database. The PROGRESS trial corroborated that as well as their own real-world evidence publication two weeks ago now. So the field is now moving towards an understanding that ventricular function or dysfunction really is one that precipitates aortic stenosis, and we need to be able to address the disease at both the valve and the ventricle across mild and moderate AS, so a larger addressable patient population likely for a TASAGUAP.

I would add to that, Dennis, just at the AHA as well, similar conclusions are being drawn independently from studies like the PROGRESS study from Edwards, And when you start looking at essentially what was heretofore kind of hidden cardiac dysfunction, as Cheryl said, 80%, that's like, that's 2 million people in the U.S. So this is a really, it's an enormous, just in mild, it's an enormous category. It's the third most prevalent cardiovascular condition after hypertension and coronary disease, and there are no approved treatments for it. So we're pretty excited about what's happening with Etosiguat, and the more we learn about how to enrich for success in these patients, we're fortunate, by the way, what did you hear Cheryl basically say? Aortic stenosis is a disease of the valve and of the myocardium. It's both. So we're going to now start talking about it that way, not just us, the whole field. We are fortunate to have a drug in Atasaguat that has a dual mechanism that impacts the calcium on the valve and also improves filling and the myocardial health. So it's exactly what you want for this condition.

Dennis Ding Analyst — Jefferies

Got it. That's super helpful. How do you distinguish, you know, because you mentioned it has a dual mechanism on the valve and on the heart, but typically with cardiovascular, it's kind of like a, what do you call it, like a. Yeah, they're linked, they're coupled, right? Like one leads to the other and back and forth. So it's like, how do you, you know, how do you have confidence that has effect on both, that is targeting both?

Cheryl Abbas Other

Yeah, so actually, if you look at the Mayo Phase II data, there's evidence that Atasaguat modifies the valve independent of that of the ventricle. Even in patients who had more of a modest reduction in AVC or a more modest decline in AVA, they still had profound improvements in systolic and diastolic function. And so this is exactly why it's important to understand how does the disease progress at both levels of the valve and the ventricle, But it's highly possible that even a modest change in calcium still will relate to significant improvements on the ventricle. And that's still a great thing. There was the debate at AHA and also from TCT with the PROGRESS trial of how do you know, is it the chicken or the egg? And the answer is, does it really matter? Because you need to treat both, right? So, and we're lucky and fortunate, as Tasso said, that we have a drug that treats both. That's what you want. And that's what we'll study.

Dennis Ding Analyst — Jefferies

So it sounds to me like the trustful market is actually much bigger than what you guys had originally envisioned. So how do you think you can, I guess, capture all that through a clinical trial or through a development path where you're able to capture all that and agree with the FDA on that sort of plan?

Cheryl Abbas Other

Yeah. So, I mean, as we move towards, you know, what they're calling clinically significant AS, the way you define it, it really is on the myocardium. It's on these echo parameters that show cardiac damage. So it's less about what is your aortic valve area, what is your calcium at baseline. It's more do you have evidence of cardiac dysfunction, which, as we said, is 80% of the population. So that gives you intel into how you could design a phase three trial or a development program, really looking at patients who have cardiac dysfunction because you know they're going to rapidly progress, And the drug is uniquely suited to address the mechanism of disease in those patients.

Dennis Ding Analyst — Jefferies

And for your Phase 3, these guys said you'll give an update in the first half of 27. What are the different scenarios of what a Phase 3 would look like?

Cheryl Abbas Other

Well, I think I'm giving good hints, I think, on the enrichment criteria as it pertains to cardiac damage. That's one aspect of it. I think you're more speaking towards the primary endpoint. And for the primary endpoint, we're lucky in that we have optionality. So aortic valve area is a good, solid, known registrational endpoint. We also know that's what determines TAVR, right, or eligibility for an aortic valve replacement. An ABA to less than one by itself is considered an outcome because you're eligible for an AVR. So we have ABA, and we have peak VO2 as a more functional endpoint and more of symptoms and feel. And the phase 2B, catalyst AV, will give us intel into both. Peak VO2 is being measured in over half of the patients. We have a CPET sub-study. We're also using ProLeo's estimated VO2 peak algorithm as a surrogate to CPET peak VO2 in all patients, in all 156 patients. So week 48 is going to give us the data we need to confirm AVA and peak VO2. But as you said, we'll share more details on the registrational trial in the first half of next year.

Dennis Ding Analyst — Jefferies

Ideally, which would you prefer? AVA, peak VO2, or a combination of the both?

The one with the highest probability of success, which also speaks more powerfully to various stakeholders. So that does include patients and prescribers. And I think on the latter, you kind of got to give the nod to AVA a little bit. It's where they live, it's what they know, and there's pull through to outcomes, but we'll see. It's great to have the choices. It could be more effective and efficient to look at peak VO2. It may not be, but it's good to have choices. By improving the myocardium, though, we should be able to improve both, and that's what we hope to see.

Dennis Ding Analyst — Jefferies

In the last minute or two, just to talk about TLA, there were some updates there. We'll get data, I believe, in second half of 27, but just help us frame that product and the opportunity.

One theme, hopefully, that you guys are taking away from the programs, both for Danicamptiv and Atasaguat, is this adaptive approach where we learn, we adjust in order to improve probability of success. The learnings are really, by and large, to match the drug mechanism to the underlying disease driver, which tends to result in enriching the patient population. We know what these drugs do. TLA is a great example of this. We're targeting angiotestinogen. It's an ASO. There's a lot on the literature of this biology and how it's important to reducing blood pressure. What we're on the search for in our studies is who uniquely, what patient uniquely requires a reduction in AGT that still has a significant unmet medical need. We're looking for places where current treatments are not effective. Generic ASOs and ARBs, that's not where we want to be. We don't want to be where ASIs can be effective, and we don't want to be where necessarily siRNAs that have a six-month half-life could be useful. So we're learning about a patient population in our 202 study that is in and out of the hospital with hypertensive emergency that has heart failure and has kidney failure. And in all of those areas, managing the vasculature and the hypertension, again, this is all causality, right to your point before. The RAS pathway and RAS escape and needing to get upstream AGT under control seems to be really relevant. There's a few million of these people that are essentially at, they engage with the hospital system at 180, 110, systolic and diastolic, and who are trending towards end organ damage. We want to help slow that down. We're going to do that by managing their blood pressure. And for us, we learned a lot about this patient population by launching the study, right? We've made some adjustments to the study based on those learnings, also by doing some pretty intensive, maybe the most comprehensive, you know, Chart and EMR reviews that have ever been done in this population, and now we're set up for some success in the second half of the year.

Dennis Ding Analyst — Jefferies

Perfect. Well, I think that's all the time that we have, but it's great seeing you guys, and thanks for hanging out with us.

Appreciate it, Dennis. A lot of data coming up. Hopefully, we'll be here talking to you about it again soon. Thanks for having us.

Analyst Q&A · 1 question
Full-screen source Call document